Head to head
BPC-157 against Pentadeca Arginate
Pentadeca arginate is sold as an improved BPC-157. It is the same 15 amino acid sequence with an arginine salt instead of acetate, created as a compounding workaround, and it has no studies of its own.
Column A
BPC-157Body Protection Compound 157
A pentadecapeptide with a large animal literature on tendon, ligament, muscle and gut healing, and a small human record: two rectal-enema studies run in Croatia, three uncontrolled clinic reports, and a randomized Phase 2 injury trial now recruiting.
Column B
Pentadeca ArginatePentadeca Arginate (PDA, pentadecapeptide arginate)
The same 15 amino acid sequence as BPC-157 with an arginine salt instead of acetate, created as a compounding workaround; it has no studies of its own and inherits BPC-157's animal-only evidence.
The mistake this page exists to correct
Vendors present pentadeca arginate as a more stable next generation peptide with its own advantages. The sequence is identical to BPC-157; what differs is the counterion. There is no published human or animal study of the arginate form specifically, so every efficacy claim made for it is borrowed from BPC-157's literature, which is itself almost entirely preclinical. A systematic review of BPC-157 found 36 studies, 35 of them preclinical.
Side by side, on the facts we can check
| Attribute | BPC-157 | Pentadeca Arginate |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| FDA status | Not FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6, one abstention, to recommend for compounding (July 2026) against the FDA reviewers' recommendation; awaiting FDA action | Not approved; not an FDA-recognized distinct substance |
| Half-life | Under 30 minutes in plasma in a two-person pilot; the animal literature describes effects lasting hours to days. | No human pharmacokinetics for either salt form |
| Molecular weight | 1,419.5 Da | 1,419.5 Da for the BPC-157 pentadecapeptide it is based on; supplied as the arginate salt, which is heavier |
| Mechanism | In animal work BPC-157 promotes angiogenesis, interacts with the nitric oxide system, and raises growth hormone receptor expression and growth factor signaling in tendon fibroblasts. No receptor or molecular target has been identified, which FDA's 2026 evaluation gave as one reason it could not judge biological plausibility. Human mechanistic work is limited to the observation that the peptide was not detectable in plasma after rectal dosing, and to a two-person pilot consistent with a plasma half-life under 30 minutes, against effects that animal studies describe as lasting hours to days. | Presumed identical to BPC-157: FAK-paxillin, VEGFR2 and nitric-oxide signaling supporting angiogenesis and tissue repair in animal models. |
| Human studies cited | 5 | 0 |
| Legal status, US | Not approved; research use only | Not approved; sold 'for research use only' |
Frequently asked questions
What is the difference between BPC-157 and Pentadeca Arginate?
BPC-157: A pentadecapeptide with a large animal literature on tendon, ligament, muscle and gut healing, and a small human record: two rectal-enema studies run in Croatia, three uncontrolled clinic reports, and a randomized Phase 2 injury trial now recruiting. Pentadeca Arginate: The same 15 amino acid sequence as BPC-157 with an arginine salt instead of acetate, created as a compounding workaround; it has no studies of its own and inherits BPC-157's animal-only evidence.
Which has stronger research evidence, BPC-157 or Pentadeca Arginate?
This database does not grade compounds. It counts what was run in people: 5 of the 12 studies cited on the BPC-157 profile were human work, against 0 of 3 for Pentadeca Arginate. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are BPC-157 and Pentadeca Arginate FDA-approved?
BPC-157: Not FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6, one abstention, to recommend for compounding (July 2026) against the FDA reviewers' recommendation; awaiting FDA action. Pentadeca Arginate: Not approved; not an FDA-recognized distinct substance.
Related posts
Blog articles that cover BPC-157 or Pentadeca Arginate, newest first.
- Healing & Recovery / Sep 8, 2026 / 9 minPeptides for Joint Pain: BPC-157, TB-500, Lorecivivint, Pentosan and Collagen Peptides, Evidence Tiered
- Healing & Recovery / Sep 8, 2026 / 8 minPeptides for Gut Health: BPC-157, KPV and Larazotide Ranked by Human Evidence
- Safety / Sep 8, 2026 / 9 minPeptide Side Effects by Class: What Is Documented, What Is Anecdotal
- Safety / Sep 8, 2026 / 8 minHow to Read a Peptide Certificate of Analysis: HPLC Purity, Mass Spec Identity, Endotoxin, and Janoshik Verification
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.